A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2 Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system, demonstrated a high procedural success rate and a low rate of paravalvular aortic regurgitation at 30 days post procedure. Results from the ACURATE neo2 CE-Mark Study, a single-arm, multi-center study, were presented at the annual congress of PCR London Valves, in Lon...

Boston Scientific has announced that the U.S. FDA has approved the Spectra WaveWriter Spinal Cord Stimulator (SCS) System. It is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy. The system allows physicians and patients to combine therapeutic options, customise therapy and capture real-time feedback designed to treat chronic and debilitating pain successfully.

Boston Scientific has announced that it has received approval from the US FDA for the Vercise Deep Brain Stimulation (DBS) System. DBS is used to treat the symptoms of Parkinson's disease (PD), a degenerative condition that affects more than one million people in the United States and ten million worldwide. DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse...

  Boston Scientific has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management.